Article
Oncology
Eline E. F. Verreck, Julia E. C. van Steenhoven, Anne Kuijer, Marissa C. van Maaren, Janine M. Simons, Sabine Siesling, Thijs van Dalen
Summary: A study found that the frequency of ALND in SLN+ breast cancer patients undergoing mastectomy significantly decreased over time, while the frequency of PMRT increased. Factors such as age, tumor subtype, N stage, and hospital type affected the likelihood of patients undergoing ALND.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Isaac Cebrecos, Eduard Mension, Inmaculada Alonso, Helena Castillo, Esther Sanfeliu, Sergi Vidal-Sicart, Sergi Ganau, Maria Vidal, Francesco Schettini
Summary: In early stage breast cancer patients without lymph node metastasis, the presence of positive sentinel lymph nodes after primary systemic treatment directs axillary lymph node dissection. This study aimed to identify factors associated with non-sentinel lymph node involvement and develop a predictive score. The results showed that non-sentinel lymph node involvement was infrequent (22.2%) and associated with progesterone receptor levels and macrometastatic sentinel lymph nodes. The developed predictive score accurately predicted the absence of non-sentinel lymph node involvement, suggesting that unnecessary axillary lymph node dissection could be safely avoided in most patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Maria Cristina Leonardi, Camilla Arrobbio, Sara Gandini, Stefania Volpe, Francesca Colombo, Eliana La Rocca, Viviana Galimberti, Sabrina Kahler-Ribeiro-Fontana, Cristiana Fodor, Samantha Dicuonzo, Damaris Patricia Rojas, Maria Alessia Zerella, Anna Morra, Emilia Montagna, Marco Colleoni, Giovanni Mazzarol, Laura Lavinia Travaini, Mattia Zaffaroni, Paolo Veronesi, Roberto Orecchia, Barbara Alicja Jereczek-Fossa
Summary: This study aimed to evaluate the rate of positive non-sentinel lymph nodes in breast cancer patients after neoadjuvant systemic therapy following positive sentinel lymph node biopsy. Positive non-SLNs were found in 62.3% of cases and were significantly associated with older age, clinically positive lymph nodes, SLN extracapsular extension, and a higher ratio of positive SLNs/total SLNs. ECE and higher nodal ratio were independent predictors of III axillary level positivity.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Ya Qiu, Xiang Zhang, Zhiyuan Wu, Shiji Wu, Zehong Yang, Dongye Wang, Hongbo Le, Jiaji Mao, Guochao Dai, Xuwei Tian, Renbing Zhou, Jiayi Huang, Lanxin Hu, Jun Shen
Summary: The MRI-clinical-radiomics nomograms developed in this study showed high predictive performance in determining axillary NSLN status in SLN-positive breast cancer patients, reducing overtreatment and optimizing personalized surgical strategies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Amit Goyal, G. Bruce Mann, Lesley Fallowfield, Lelia Duley, Malcolm Reed, David Dodwell, Robert E. Coleman, Apostolos Fakis, Robert Newcombe, Valerie Jenkins, Diane Whitham, Margaret Childs, David Whynes, Vaughan Keeley, Ian Ellis, Patricia Fairbrother, Shabina Sadiq, Kathryn Monson, Alan Montgomery, Wei Tan, Luke Vale, Tara Homer, Heath Badger, Rachel Helen Haines, Mickey Lewis, Daniel Megias, Zohal Nabi, Preetinder Singh, Andrei Caraman, Elizabeth Miles
Summary: The POSNOC trial aims to evaluate whether adjuvant therapy alone is non-inferior to adjuvant therapy plus axillary treatment for breast cancer patients with 1 or 2 macrometastases in terms of 5-year axillary recurrence.
Article
Oncology
Toralf Reimer
Summary: The local treatment of axilla in early breast cancer patients without clinically evident lymph node metastases is a subject of debate. Various prospective randomized surgical trials are currently being conducted to evaluate the safety of omitting sentinel lymph node biopsy in upfront breast-conserving surgery and neoadjuvant setting. These trials aim to determine whether it is possible to make therapeutic decisions without pathologic evaluation of nodal status. Additionally, ongoing trials are investigating the possibility of de-escalating surgery based on the response to neoadjuvant systemic therapy.
Article
Oncology
Xunxi Lu, Mengting He, Luoting Yu, Zongchao Gou
Summary: This cohort study found that receiving surgical axillary staging was associated with better survival for patients with ipsilateral breast tumor recurrence, and repeat sentinel lymph node biopsy had a similar long-term survival outcome as axillary lymph node dissection. Therefore, repeat sentinel lymph node biopsy may be considered for surgical axillary staging in patients with ipsilateral breast tumor recurrence after lumpectomy and initial sentinel lymph node biopsy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiang Zhang, Zehong Yang, Wenju Cui, Chushan Zheng, Haojiang Li, Yudong Li, Liejing Lu, Jiaji Mao, Weike Zeng, Xiaodong Yang, Jian Zheng, Jun Shen
Summary: A multiparametric MRI-based radiomics nomogram was developed and validated for predicting axillary sentinel lymph node burden in early-stage breast cancer. The nomogram showed good calibration and outperformed MRI-determined axillary lymph node burden alone, as well as MRI-based descriptors of primary breast tumor, in terms of predicting sentinel lymph node burden.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Amparo Garcia-Tejedor, Carlos Ortega-Exposito, Sira Salinas, Ana Luzardo-Gonzalez, Catalina Falo, Evelyn Martinez-Perez, Hector Perez-Montero, M. Teresa Soler-Monso, Maria-Teresa Bajen, Ana Benitez, Raul Ortega, Anna Petit, Anna Guma, Miriam Campos, Maria J. Pla, Sonia Pernas, Judith Penafiel, Carlos Yeste, Miguel Gil-Gil, Ferran Guedea, Jordi Ponce, Maria Laplana
Summary: This study aims to evaluate whether axillary radiotherapy (ART) is non-inferior to axillary lymph node dissection (ALND) in patients with limited lymphatic involvement after neoadjuvant systemic treatment (NST), and whether it reduces surgery-related adverse effects.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ji Young You, Eun Sook Lee, Siew Kuan Lim, Youngmee Kwon, So-Youn Jung
Summary: According to the study, performing sentinel lymph node biopsy (SLNB) without axillary lymph node dissection (ALND) may be a reasonable treatment option for patients with positive lymph nodes after breast cancer surgery. There was no significant difference in the loco-regional recurrence rates between SLNB with ALND and SLNB alone.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Nadia Maggi, Rahel Nussbaumer, Liezl Holzer, Walter P. Weber
Summary: Long-term follow-up data from multicenter phase III non-inferiority trials confirmed the safety of omitting axillary dissection in selected patients with clinically node-negative, sentinel node-positive breast cancer. Ongoing trials are investigating the extended eligibility of the Z0011 protocol in the adjuvant setting. De-escalation of axillary surgery in patients with clinically node-positive breast cancer is currently limited to the neoadjuvant setting.
Article
Oncology
Masakuni Noguchi, Masafumi Inokuchi, Miki Yokoi-Noguchi, Emi Morioka, Yusuke Haba, Tomoko Takahashi, Akihiro Shioya, Sohsuke Yamada
Summary: Axillary reverse mapping (ARM) nodes are involved in a significant proportion of clinically node-positive breast cancer patients. Neoadjuvant chemotherapy (NAC) effectively reduces the incidence of nodal metastases in these patients. However, the rate of ARM node metastases after NAC is still too high to spare ARM nodes. F-18-FDG-PET/CT can detect a low risk of ARM node metastases after NAC, but it is not suitable for detecting residual metastatic disease in the axilla. Therefore, suspicious ARM nodes must be removed while sparing ARM lymphatics to minimize arm lymphedema.
Article
Oncology
Austin D. Williams, Karen Ruth, Saba S. Shaikh, Mahtab Vasigh, Mary T. Pronovost, Allison A. Aggon, Andrea S. Porpiglia, Richard J. Bleicher
Summary: Patients with one +SLN without high-risk features are unlikely to have >= 4 +LNs and should not undergo axillary lymph node dissection to determine candidacy for abemaciclib. A multidisciplinary discussion should be conducted to weigh the morbidity of ALND and the potential benefit of abemaciclib for those with two +SLNs.
Article
Oncology
James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John Kiluk, M. Catherine Lee
Summary: The study found that completion axillary lymph node dissection (CLND) after mastectomy did not significantly reduce recurrence or improve overall survival (OS) in clinically node-negative, sentinel lymph node (SLN)-positive breast cancer patients. However, completion of postmastectomy radiotherapy was associated with improved OS.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Medicine, General & Internal
Neil Carleton, Jian Zou, Yusi Fang, Stephen E. Koscumb, Osama Shiraz Shah, Fangyuan Chen, Sushil Beriwal, Emilia J. Diego, Adam M. Brufsky, Steffi Oesterreich, Steven D. Shapiro, Robert Ferris, Leisha A. Emens, George Tseng, Oscar C. Marroquin, Adrian V. Lee, Priscilla F. McAuliffe
Summary: This study found that receiving SLNB or RT did not improve LRFS or DFS in older patients with ER-positive, clinically node-negative breast cancer. The study supports the continued deimplementation of both SLNB and RT in accordance with the Choosing Wisely and National Comprehensive Cancer Network guidelines.
Article
Oncology
Daphne Schouten, Rob van Os, Anneke M. Westermann, Hans Crezee, Geertjan van Tienhoven, Willemijn M. Kolff, Adriaan D. Bins
Summary: Adding cisplatin to reirradiation and hyperthermia does not show potential benefit in patients with recurrent breast cancer in previously irradiated areas. Most patients can achieve local control regardless of cisplatin use.
Article
Oncology
Josephine M. N. Lopes Cardozo, Caroline A. Drukker, Emiel J. T. Rutgers, Marjanka K. Schmidt, Annuska M. Glas, Anke Witteveen, Fatima Cardoso, Martine Piccart, Laura J. Esserman, Coralie Poncet, Laura J. van't Veer
Summary: Through studying patients with a 70-gene signature ultralow-risk breast cancer, it was found that these patients have excellent prognosis, with an 8-year breast cancer-specific survival rate above 99%, suggesting that they could be candidates for further de-escalation of treatment to avoid overtreatment and the risk of side effects.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Akke Bakker, C. Paola Tello Valverde, Geertjan van Tienhoven, M. Willemijn Kolff, H. Petra Kok, Ben J. Slotman, Inge R. H. M. Konings, Arlene L. Oei, Hester S. A. Oldenburg, Emiel J. T. Rutgers, Coen R. N. Rasch, H. J. G. Desiree van den Bongard, Hans Crezee
Summary: The study investigated the impact of hyperthermia thermal dose on locoregional control, overall survival, and toxicity in patients with locoregional recurrent breast cancer treated with postoperative re-irradiation and hyperthermia. The results showed that a high thermal dose was associated with significantly higher locoregional control without increasing toxicity.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
J. M. N. Lopes Cardozo, D. Byng, C. A. Drukker, M. K. Schmidt, M. A. Binuya, L. J. van 't Veer, F. Cardoso, M. Piccart, C. H. Smorenburg, C. Poncet, E. J. T. Rutgers
Summary: In patients with stage I low-risk breast cancer, adjuvant endocrine therapy has a limited effect on distant metastasis-free interval (DMA), but significantly reduces breast cancer events.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Walter Paul Weber, Jane Shaw, Andrea Pusic, Lynda Wyld, Monica Morrow, Tari King, Zoltan Matrai, Joerg Heil, Florian Fitzal, Shelley Potter, Isabel T. Rubio, Maria-Joao Cardoso, Oreste Davide Gentilini, Viviana Galimberti, Virgilio Sacchini, Emiel J. T. Rutgers, John Benson, Tanir M. Allweis, Martin Haug, Regis R. Paulinelli, Tibor Kovacs, Yves Harder, Bahadir M. Gulluoglu, Eduardo Gonzalez, Andree Faridi, Elisabeth Elder, Peter Dubsky, Jens-Uwe Blohmer, Vesna Bjelic-Radisic, Mitchel Barry, Susanne Dieroff Hay, Kimberly Bowles, James French, Roland Reitsamer, Rupert Koller, Peter Schrenk, Daniela Kauer-Dorner, Jorge Biazus, Fabricio Brenelli, Jaime Letzkus, Ramon Saccilotto, Sarianna Joukainen, Susanna Kauhanen, Ulla Karhunen-Enckell, Juergen Hoffmann, Ulrich Kneser, Thorsten Kuhn, Michalis Kontos, Ekaterini Christina Tampaki, Moshe Carmon, Tal Hadar, Giuseppe Catanuto, Carlos A. Garcia-Etienne, Linetta Koppert, Pedro F. Gouveia, Jakob Lagergren, Tor Svensjoe, Nadia Maggi, Elisabeth A. Kappos, Fabienne D. Schwab, Liliana Castrezana, Daniel Steffens, Janna Krol, Christoph Tausch, Andreas Gunthert, Michael Knauer, Maria C. Katapodi, Susanne Bucher, Nik Hauser, Christian Kurzeder, Rosine Mucklow, Pelagia G. Tsoutsou, Atakan Sezer, Guldeniz Karadeniz Cakmak, Hasan Karanlik, Patricia Fairbrother, Laszlo Romics, Giacomo Montagna, Cicero Urban, Melanie Walker, Silvia C. Formenti, Guenther Gruber, Frank Zimmermann, Daniel Rudolf Zwahlen, Sherko Kuemmel, Mahmoud El-Tamer, Marie Jeanne Vrancken Peeters, Orit Kaidar-Person, Michael Gnant, Philip Poortmans, Jana de Boniface
Summary: The aim of this article is to discuss the demand for nipple-and skin-sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) and present clinical practice recommendations in the context of expanded indications for post-mastectomy radiation therapy (PMRT). The panel agrees that surgical technique for NSM/SSM should not be modified when PMRT is planned, with preference for autologous over implant-based BR. However, no specific recommendations are made regarding implant positioning, use of mesh or timing. The use of patient-reported outcomes in clinical practice is endorsed. The article emphasizes the importance of prospective randomized phase III studies and interdisciplinary collaboration for determining optimal sequencing and techniques for PMRT in the context of BR.
Article
Oncology
Sonja B. Vliek, Florentine S. Hilbers, Agnes Jager, Valesca P. Retel, Jolien M. Bueno de Mesquita, Caroline A. Drukker, Sanne C. Veltkamp, Anneke M. Zeillemaker, Emiel J. Rutgers, Harm van Tinteren, Wim H. van Harten, Laura J. van 't Veer, Marc J. van de Vijver, Sabine C. Linn
Summary: This study provides long-term outcome data for ER-positive, HER2-negative breast cancer patients classified by clinical and genomic risk categories. It demonstrates that clinically high-risk, genomically low-risk tumors have excellent outcomes in the context of shared decision-making. The study also suggests that genomic ultralow-risk tumors may have a favorable prognosis even without systemic therapy.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Sophie C. Hagenaars, Lennard J. M. Dekker, Bob Ravesteijn, Ronald L. P. van Vlierberghe, Fred P. H. T. M. Romijn, Linda Verhoeff, Arjen J. Witkamp, Karin E. Schenk, Kristien B. I. M. Keymeulen, Marian B. E. Menke-Pluijmers, Anneriet E. Dassen, Birgitta A. Kortmann, Jakob de Vries, Emiel J. T. Rutgers, Yuri E. M. van der Burgt, Elma Meershoek-Klein Kranenbarg, Christa M. Cobbaert, Theo M. Luider, Wilma E. Mesker, Rob A. E. M. Tollenaar
Summary: The TESTBREAST study aims to identify a novel panel of blood-based protein biomarkers for early breast cancer detection in moderate-to-high-risk women. Longitudinal measurements of protein levels in serum samples revealed a greater interpatient than intrapatient variability, and identified specific proteins associated with the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Sanne A. L. Bartels, Mila Donker, Coralie Poncet, Nicolas Sauve, Marieke E. E. Straver, Cornelis J. H. van de Velde, Robert E. E. Mansel, Charlotte Blanken, Lorenzo Orzalesi, Jean H. G. Klinkenbijl, Huub C. J. van der Mijle, Grard A. P. Nieuwenhuijzen, Sanne C. C. Veltkamp, Thijs van Dalen, Andreas Marinelli, Herman Rijna, Marko Snoj, Nigel J. J. Bundred, Jos W. S. Merkus, Yazid Belkacemi, Patrick Petignat, Dominic A. X. Schinagl, Corneel Coens, Geertjan van Tienhoven, Frederieke van Duijnhoven, Emiel J. T. Rutgers
Summary: This clinical trial compared axillary lymph node dissection (ALND) with axillary radiotherapy (ART) in patients with cT1-2, node-negative breast cancer. The study found that both modalities had comparable axillary control, but ART was associated with less morbidity. Additionally, patients in the ART group had a higher risk of developing second primary cancers.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Josephine M. N. L. Cardozo, Irene L. E. Andrulis, Stig E. Bojesen, Thilo M. Doerk, Diana M. A. Eccles, Peter A. J. Fasching, Maartje J. Hooning, Renske Keeman, Heli Nevanlinna, Emiel J. T. F. Rutgers, Douglas F. Easton, Per Hall, Paul D. P. J. Pharoah, Laura J. K. van't Veer, Marjanka K. Schmidt
Summary: A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer. The results showed that PRS313 is associated with favorable tumor characteristics but not independently associated with prognosis. Rating: 8/10.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Surgery
Martine A. van Huizum, J. Joris Hage, Astrid N. Scholten, Emiel J. Rutgers
JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY
(2023)
Article
Oncology
Annemiek K. E. van Hemert, Josefien P. P. van Olmen, Liesbeth J. J. Boersma, John H. H. Maduro, Nicola S. S. Russell, Jolien Tol, Ellen G. G. Engelhardt, Emiel J. Th. Rutgers, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke H. H. van Duijnhoven
Summary: The purpose of this study is to show that omitting adjuvant radiotherapy in breast cancer patients with pCR after NST can result in low rates of local recurrence and good quality of life.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Oncology
Marjanka K. Schmidt, Jennifer E. Kelly, Anne Bredart, David A. Cameron, Jana de Boniface, Douglas F. Easton, Birgitte Offersen, Fiorita Poulakaki, Isabel T. Rubio, Francesco Sardanelli, Rita Schmutzler, Tanja Spanic, Britta Weigelt, Emiel J. T. Rutgers
Summary: After a unilateral breast cancer diagnosis, more and more patients are choosing to have contralateral prophylactic mastectomy (CPM), the removal of the healthy breast. Breast cancer specialists need to provide guidance to women considering CPM. This manifesto discusses the challenges of CPM and offers recommendations to improve outcomes for women with unilateral breast cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Quisette P. Janssen, Rutger Quispel, Marc G. Besselink, Bert A. Bonsing, Marco J. Bruno, Michael Doukas, Arantza F. Sarasqueta, Marjolein Y. V. Homs, Jeanin E. van Hooft, Geertjan van Tienhoven, Marie-Louise F. van Velthuysen, Joanne Verheij, Rogier P. Voermans, Johanna W. Wilmink, Bas Groot Koerkamp, Casper H. J. van Eijck, Lydi M. J. W. van Driel
Summary: This study evaluates the performance of endoscopic tissue acquisition procedures for borderline resectable and resectable pancreatic ductal adenocarcinoma (PDAC). The results show that EUS-guided tissue acquisition had a sensitivity of over 85% for both initial and repeat procedures, meeting international standards.
Review
Gastroenterology & Hepatology
Thomas F. Stoop, Rutger T. Theijse, Leonard W. F. Seelen, Bas Groot Koerkamp, Casper H. J. van Eijck, Christopher L. Wolfgang, Geertjan van Tienhoven, Hjalmar C. van Santvoort, I. Quintus Molenaar, Johanna W. Wilmink, Marco Del Chiaro, Matthew H. G. Katz, Thilo Hackert, Marc G. Besselink
Summary: Surgical resection combined with systemic chemotherapy is the main treatment approach for localized pancreatic cancer. Preoperative chemotherapy and radiotherapy are commonly used in cases with extensive vascular involvement. Treatment selection is based on anatomical, biological, and conditional parameters. Current guidelines and clinical practices vary in terms of preoperative therapy, response evaluation, and surgical decision-making.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Meeting Abstract
Oncology
Josephine Lopes Cardozo, Irene L. Andrulis, Devilee Peter, Thilo Doerk, Caroline Drukker, Peter A. Fasching, Maartje J. Hooning, Renske Keeman, Heli Nevanlinna, Emiel J. Rutgers, Laura van 't Veer, Per Hall, Stig Egil Bojesen, Easton Douglas, Diana Eccles, Paul Pharoah, Marjanka Schmidt
JOURNAL OF CLINICAL ONCOLOGY
(2022)